OGEN
Oragenics, Inc.
Set alert
0.37 USD 0.00 -0.05%
0.3711 Day range 0.3855
0.37 52-week range 1.23
- YTD
- -52.05%
- 1 year
- -69.59%
- Open
- 0.3727
- Prev close
- 0.3742
- Mkt cap
- 1.69M
- Vol
- 9.21K
- Avg vol
- 29.24K
- EPS
- -2.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3711
- High
- 0.3855
- Forward P/E
- -0.03
- Beta
- 0.48
- Short ratio
- 0.43
- Inst. own
- 11.13%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.3272
- 200-d avg
- 0.981
- 1y target
- 0.00
Key statistics
- Market cap
- 4.47M
- Enterprise value
- 2.08M
- Trailing P/E
- 0.00
- Forward P/E
- -0.03
- PEG ratio
- 0.00
- Price / sales
- 598.95
- Price / book
- 0.72
- EPS (TTM)
- -6.97
- Beta
- 0.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.47K
- Revenue growth
- 0.00%
- Free cash flow
- -9.52M
- Total cash
- 1.35M
- Total debt
- 0
- Return on equity
- -454.72%
- Shares outstanding
- 12.23M
- Short % of float
- 2.15%
- 50-day average
- 0.3272
- 200-day average
- 0.981
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
OGEN Revenue — quarterly 0
OGEN Net income — quarterly -2.53M
OGEN EPS — quarterly -0.57
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.38 | — | — |
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | -0.51 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.70 | — | — |
| Mar 29, 2024 | Dec 1, 2023 | 0.00 | -5.48 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.85 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -1.51 | — | — |
About Oragenics, Inc.
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- oragenics.com
News
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards
- Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY
- Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics
- Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury
- Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002
- Oragenics Completes First Site Initiation Visit For Its Phase IIa Clinical Study Of ONP-002 In Australia
- Oragenics Explores Acquisition Of Additional Assets In Central Nervous System Space; No Definitive Agreements Signed
- Oragenics Receives Approval From Australia's Human Research Ethics Committee To Start Phase IIa Clinical Study Of ONP-002 For Concussion Treatment
- Oragenics Previews 2026 Milestones; Outlines Clinical And Growth Catalysts For ONP-002 In Concussion And mTBI
Your note
Sign in to keep a note on OGEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DUNTON ALAN WILLIAM | Director | Sale | Dec 5, 2024 | 25,623 |
| HUFFMAN JANET | Chief Financial Officer | Stock Award(Grant) | Aug 7, 2023 | 15,000 |
| KOSKI ROBERT C | Director | Conversion of Exercise of derivative security | Dec 10, 2024 | 0 |
| MURPHY KIMBERLY M | Chief Executive Officer | Stock Award(Grant) | Aug 7, 2023 | 25,000 |
| POPE CHARLES L | Director | Stock Award(Grant) | Aug 7, 2023 | 25,471 |
| TELLING FREDERICK W | Director | Sale | Dec 5, 2024 | 34,748 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.29% | 35,721 | 13.06K | Sep 29, 2024 |
| HRT Financial LP | 0.23% | 27,918 | 10.20K | Sep 29, 2024 |
| GSB Wealth Management, LLC | 0.17% | 20,202 | 7.38K | Sep 29, 2024 |
| Blackrock Inc. | 0.17% | 21,059 | 7.70K | Sep 29, 2024 |
| Virtu Financial LLC | 0.17% | 20,871 | 7.63K | Sep 29, 2024 |
| Lionsbridge Wealth Management LLC | 0.16% | 20,000 | 7.31K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.24% | 29,563 | 10.80K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.07% | 8,866 | 3.24K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.06% | 7,334 | 2.68K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 6,126 | 2.24K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.01% | 1,390 | 508 | Oct 30, 2024 |